ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Agilent doubles oligonucleotide manufacturing

by Ryan Cross
June 29, 2019 | APPEARED IN VOLUME 97, ISSUE 26

 

09726-buscon16-agilentcxd.jpg
Credit: Agilent
A quality-control lab at Agilent's Frederick, Colorado, facility

Agilent Technologies has opened a 12,500 m2 oligonucleotide production plant in Frederick, Colorado, to meet growing demand for the RNA and DNA molecules that biotech firms are developing as therapies for many diseases. The $185 million facility will complement its oligo plant in nearby Boulder. The two sites are equipped to make oligos for antisense, RNA interference, and immune-stimulating therapies, as well as guide RNAs used to direct gene editing. Agilent anticipates shipping orders from the site later this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment